SciELO - Scientific Electronic Library Online

 
vol.82 número4Enfermedad de Moyamoya: Cefalea crónica y demencia progresiva asociadas a infartos cerebrales múltiplesSíndrome neuroléptico maligno debido a ziprasidona: reporte de un caso índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista de Neuro-Psiquiatría

versión impresa ISSN 0034-8597

Resumen

MUNOZ, Omar H; VARGAS-RODRIGUEZ, Ledmar J; BENAVIDEZ-JIMENEZ, Hernando A  y  VEGA- SEPULVEDA, Ana C. Malignant neuroleptic syndrome induced by risperidone and facilitated by sepsis of urinary origin: clinical aspects and physiopathology. Rev Neuropsiquiatr [online]. 2019, vol.82, n.4, pp.293-297. ISSN 0034-8597.  http://dx.doi.org/10.20453/rnp.v82i4.3651.

Risperidone is a selective monoaminergic antagonist with a high affinity for dopamine receptors that can cause neuroleptic malignant syndrome (NMS), considered a life-threatening medical emergency. It has an incidence of up to 3% and its mortality is between 10 and 20%. The case of a 56-year-old female who met the clinical criteria of NMS, induced by the use of risperidone and facilitated by a sepsis of urinary origin, is reported. It was managed with a dopamine agonist and the change of antipsychotic, which resulted in a favorable clinical course. The NMS is a low-prevalence entity whose diagnosis has specificity and sensitivity greater than 90%, reason for which must be clearly differentiated from other pathologies. The mechanism by which urinary infection could facilitate the occurrence of this disease is discussed. Early diagnosis improves the response to an adequate management to be established in each case.

Palabras clave : Neuroleptic malignant syndrome; sepsis; tract urinary; infection; risperidone; antipsychotic agents.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons